Table 7.

Lesion-based quantification parameters in T1 and T2

Parameter	Prostatic lesions T1 [mean; CI]	Prostatic lesions T2 [mean; CI]	p	Lymphonodal lesions T1 [mean; CI]	Lymphonodal lesions T2 [mean; CI]	p	Bone lesions T1 [mean; CI]	Bone lesions T2 [mean; CI]	p	All lesions T1 [mean; CI]	All lesions T2 [mean; CI]	p
Score	2.33; 2.06–2.60	1.50; 1.07–1.93	0.001	2.00; 1.82–2.18	0.61; 0.35–0.86	< 0.001	1.52; 1.26–1.78	0.48; 0.22–0.74	< 0.001	1.94; 1.81–2.08	0.77;0.58–0.96	< 0.001
SUVmax	29.13; 20.11–38.15	14.67; 9.02–20.32	0.002	20.65; 15.50–25.81	8.17; 2.79–13.55	< 0.001	12.84; 8.27–17.41	3.48; 1.30–5.65	< 0.001	20.44; 16.86–24.02	8.35; 5.24–11.46	< 0.001
SUVmean	17.44; 11.99–22.89	8.63; 5.36–11.90	0.003	13.48; 10.09–16.86	5.10; 1.80–8.41	< 0.001	8.36; 5.37–11.36	2.20; 0.80–3.61	< 0.001	12.99; 10.72–15.26	5.11; 3.22–7.00	< 0.001
PSMA-TV [ml]	11.82; 8.13–15.51	3.32; 1.52–5.13	< 0.001	2.99; 1.39–4.60	0.23; 0.08–0.39	< 0.001	1.88; 1.24–2.52	0.98; 0.23–1.75	0.013	4.64; 3.29–5.98	1.12; 0.63 -1.60	< 0.001
TL-PSMA [ml]	253.16; 104.63–401.70	33.95; 9.68–58.22	< 0.001	41.62; 19.70–63.53	4.62; 0–10.48	< 0.001	21.03; 4.49–34.57	6.33; 0–13.65	< 0.001	82.72; 45.49–119.94	11.53; 4.99–18.07	< 0.001